ResMed Form 144: planned sale of 2,000 shares valued at $504,100
ResMed (RMD): Form 144 filed for a planned sale of up to 2,000 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ResMed (RMD): Form 144 filed for a planned sale of up to 2,000 common shares. The notice lists an aggregate market value of $504,100, with sales expected on or about 11/12/2025 on the NYSE through Merrill Lynch (2049 Century Park East, Ste 1200, Los Angeles, CA 90067). This is a resale by a security holder under Rule 144; proceeds would go to the seller, not the company.
The filing shows the issuer had 44,448,959 shares outstanding. The shares to be sold were acquired on 09/01/2014 via a stock option for cash, in the amount of 2,000 shares, from Peter C Farrell.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ResMed (RMD) disclose in this Form 144?
What is the aggregate market value of the planned sale for RMD?
Which broker is listed for the Form 144 sale for RMD?
Will ResMed receive any proceeds from this Form 144 sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.